Compounds > viroxime
Page last updated: 2024-12-11

viroxime

Cross-References

ID SourceID
PubMed CID5748733
CHEMBL ID283403
SCHEMBL ID3585
MeSH IDM0076753

Synonyms (47)

Synonym
ar-336
ly-122772
enviroxime
nsc346230
nsc-346230
72301-79-2
enviroxime (usan/inn)
63198-97-0
D04012
1h-benzimidazol-2-amine, 6-[(e)-(hydroxyimino)phenylmethyl]-1-[(1-methylethyl)sulfonyl]-
enviroxima [inn-spanish]
enviroximum [inn-latin]
(e)-2-amino-6-benzoyl-1-(isopropylsulfonyl)benzimidazole oxime
1h-benzimidazol-2-amine, 6-((hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-, (e)-
1h-benzimidazol-2-amine, 6-((e)-(hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-
viroxime component b
nsc 346230
enviroxime [usan:inn]
CHEMBL283403
ly 122772
(ne)-n-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine
enviroximum
unii-133013l556
enviroxima
133013l556 ,
(z,e)-2-amino-6-benzoyl-1-(isopropylsulfonyl)benzimidazol oxim
ly 122771-72
6-((hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-1h-benzimidazol-2-amine
1h-benzimidazol-2-amine, 6-((hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-
viroxime
ar 336
2-amino-1-(isopropylsulfonyl)-6-benzimidazole phenyl ketone oxime
lilly 122771-72
unii-i5v34wg2be
i5v34wg2be ,
viroxime [usan:inn]
enviroxime [inn]
enviroxime [usan]
enviroxime [mi]
SCHEMBL3585
DTXSID40222628
(1e)-[2-amino-1-[(1-methylethyl)sulfonyl]-1h-benzimidazol-6-yl]phenylmethanone oxime
EX-A7248
2-amino-6-[(e)-alpha-hydroxyiminobenzyl]-1-(isopropylsulfonyl)-1h-benzimidazole
Q27273110
6-[(e)-(hydroxyimino)phenylmethyl]-1-[(1-methylethyl)sulfonyl]- 1h-benzimidazol-2-amine
AKOS040751693

Research Excerpts

Overview

Enviroxime is an antienterovirus compound that targets viral protein 3A and/or 3AB. It suppresses a step in enterovirus replication by unknown mechanism.

ExcerptReferenceRelevance
"Enviroxime is a potent antiviral agent with broad spectrum activity in tissue culture against both rhinoviruses and enteroviruses. "( Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
Loncharich, R; Spitzer, WA; Tang, J; Victor, F, 1997)		1.27
"Enviroxime is an antienterovirus compound that targets viral protein 3A and/or 3AB and suppresses a step in enterovirus replication by unknown mechanism. "( Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.
Arita, M; Kojima, H; Nagano, T; Okabe, T; Shimizu, H; Wakita, T, 2011)		1.34
"Enviroxime is an antipicornavirus compound that targets host phosphatidylinositol 4-kinase III beta (PI4KB) activity for its antipicornavirus activity. "( Oxysterol-binding protein family I is the target of minor enviroxime-like compounds.
Arita, M; Kojima, H; Nagano, T; Okabe, T; Shimizu, H; Wakita, T, 2013)		1.35
"Enviroxime is an antiviral compound that inhibits the replication of rhinoviruses and enteroviruses. "( The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus.
Heinz, BA; Vance, LM, 1995)		1.32

Effects

ExcerptReferenceRelevance
"Enviroxime has been shown to inhibit the replication of rhinoviruses and other enteroviruses in concentrations as low as nanograms per milliliter in in vitro assays but is markedly less effective in clinical trials. "( Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes.
Gilbert, BE; Knight, V; Six, HR; Wilson, SZ; Wyde, PR, 1988)		1.23

Toxicity

ExcerptReferenceRelevance
" Free enviroxime and LE were found to have equivalent efficacies against rhinovirus strains 1A and 13 in in vitro assays; however, preparations of LE were 10- to greater than or equal to 50-fold less toxic to tissue culture cells than was free enviroxime."( Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes.
Gilbert, BE; Knight, V; Six, HR; Wilson, SZ; Wyde, PR, 1988)		0.94

Bioavailability

ExcerptReferenceRelevance
"In an effort to find an orally bioavailable antiviral for the treatment of rhino/enteroviral infections, a series of vinylacetylene benzimidazoles (11a-o, 12, and 18a) was made."( Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice.
Lee, CC; McKinney, E; Miller, SC; Sattelberg, TR; Spitzer, WA; Tang, JC; Tebbe, MJ; Victor, F, 1997)		0.3

Dosage Studied

ExcerptRelevanceReference
" This allowed a total dosage not much less than might have been given by other routes, but with the advantage that it was evenly deposited over the surface of the infected respiratory tract beginning within seconds of the start of treatment and reached higher concentration in nasal secretions than in serum."( Chemotherapy of respiratory viruses.
Gilbert, BE; Knight, V, 1986)		0.27
" Mortality was seen in all dosing groups of mice treated with either compound, therefore suggesting that short-term inhibition of PI4KIIIβ is deleterious."( Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo.
Bellavance, É; Décor, A; Desmeules, S; Franti, M; Garneau, M; Gauthier, A; Guo, T; Hucke, O; Laberge, MK; Leyssen, P; Lippens, J; Neyts, J; O'Meara, J; Spickler, C; Vaillancourt, FH, 2013)		0.39
" Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination."( A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020)		0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (134)

Assay IDTitleYearJournalArticle
AID1287135Antiviral activity against Human coxsackievirus B1 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID86322Dose required to prevent rhinovirus type 69 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID88374Antiviral activity against Rhinovirus (RV-16) in HeLa cells using CPE/XTT assay1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID644560Antiviral activity against Coxsackievirus B3 Nancy infected in african green monkey Vero cells assessed as inhibition of virus-induced cell death after 3 days by spectrophotometry based MTS/PMS assay2012European journal of medicinal chemistry, Mar, Volume: 49Efficient synthesis and anti-enteroviral activity of 9-arylpurines.
AID644569Cytotoxicity against Coxsackievirus B3 Nancy infected African green monkey Vero cells assessed as change in cell morphology at EC50 after 3 days by microscopic analysis2012European journal of medicinal chemistry, Mar, Volume: 49Efficient synthesis and anti-enteroviral activity of 9-arylpurines.
AID84728Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Glu 34 to Val).1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86671Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.00 ug/mL.1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698659Antiviral activity against Coxsackie virus B3 HA 201 933 infected in Vero 76 cells assessed as reduction in virus yield by visual inspection method2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1703103Antiviral activity against Enterovirus A71 infected in human RD cells assessed as inhibition of viral replication measured by CCK-8 assay2020European journal of medicinal chemistry, Sep-15, Volume: 202Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study.
AID557531Antiviral activity against Human rhinovirus 72 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1703105Selectivity index, ratio of CC50 for human RD cells infected with Enterovirus A71 to EC50 for Enterovirus A71 infected in human RD cells2020European journal of medicinal chemistry, Sep-15, Volume: 202Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study.
AID86324Dose required to prevent rhinovirus type 72 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84733Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Ile 77 to Val).1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID557534Antiviral activity against Human rhinovirus 45 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID84726% survivors was determined against mutants of human rhinovirus 14 by extended cycle replication assay in 1 ug/mL enviroxime by different amino acid substitution1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID644561Cytotoxicity against African green monkey Vero cells after 3 days by spectrophotometry based MTS/PMS assay2012European journal of medicinal chemistry, Mar, Volume: 49Efficient synthesis and anti-enteroviral activity of 9-arylpurines.
AID86672Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.02 ug/mL.1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID86665Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.17 ug/mL1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1287141Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells by after 24 to 36 hrs MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID47193Compound was evaluated for chemotherapeutic index in CV-1 cells (chemotherapeutic index=50% cytotoxic dose/50% effective dose)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID187079In vitro hepatic microsomal metabolism in rat1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID88372Antiviral activity against Poliovirus (PV-1) in HeLa cells using CPE/XTT assay1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID1698663Antiviral activity against Enterovirus D68 US/KY/14-18953 infected in RD cells assessed as reduction in virus yield by visual inspection method2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1287138Cytotoxicity against human RD cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557532Antiviral activity against Human rhinovirus 70 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID200189In vitro activity against Rhinovirus type 1B by plaque inhibition assay.1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
9-Benzyl-6-(dimethylamino)-9H-purines with antirhinovirus activity.
AID95482Cellular toxicity in KB cells2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
AID1287137Antiviral activity against Enterovirus 71 infected in human RD cells after 24 to 36 hrs by MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557772Antiviral activity against Human coxsackievirus B3 harboring wild type nonstructural protein 3A infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1287143Antiviral activity against Human coxsackievirus B6 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557529Antiviral activity against Human rhinovirus 86 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID105851Cellular toxicity against HRV-1A strain in MRC-5 cells; Not tested2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
AID59918In vitro hepatic microsomal metabolism in dog1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID1698660Selectivity index, ratio for CC50 of monkey Vero 76 cells to EC50 for Coxsackie virus B3 HA 201 933 by visual inspection method2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1698664Cytotoxicity against human RD cells by microscopic based visual inspection method2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1287131Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID86673Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.04 ug/mL.1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557775Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I54F mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID88711Dose required to prevent rhinovirus type 3 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84734Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Met 54 to Ile)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID557773Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I8T mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557761Antiviral activity against Human rhinovirus 2 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557755Antiviral activity against Human poliovirus 1 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1703104Cytotoxicity against human RD cells infected with Enterovirus A71 assessed as reduction in cell viability measured by CCK-8 assay2020European journal of medicinal chemistry, Sep-15, Volume: 202Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study.
AID14287Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice.
AID84741% survivors was determined against mutants of human rhinovirus 14 by extended cycle replication assay in 1 ug/mL enviroxime1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86320Dose required to prevent rhinovirus type 61 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID47192Antiviral activity against poliovirus type 1 in CV-1 cells1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID89954In vitro hepatic microsomal metabolism in human1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86317Dose required to prevent rhinovirus type 37 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID88709Dose required to prevent rhinovirus type 16 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID162231Antiviral activity against polio 1 virus using a plaque-inhibition assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID84727Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Asp 28 to Tyr).1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86663Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.04 ug/mL1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1876111Cytotoxicity against human Huh-7 cells2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID557760Antiviral activity against Human rhinovirus 89 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID88362Antiviral activity against Coxsackie virus (CoxA21) in HeLa cells using CPE/XTT assay1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID84731Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Ile 32 to Val)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID199693Antiviral activity was evaluated against rhino virus using PRA assay2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Imidazo[1,2-b]pyridazines, novel nucleus with potent and broad spectrum activity against human picornaviruses: design, synthesis, and biological evaluation.
AID199881Antiviral activity against rhinovirus 10 using plaque-inhibition assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID86677Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.75 ug/mL.1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557539Antiviral activity against Human rhinovirus 14 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID88710Dose required to prevent rhinovirus type 20 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557530Antiviral activity against Human rhinovirus 85 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID86319Dose required to prevent rhinovirus type 50 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698662Selectivity index, ratio for CC50 of monkey Vero 76 cells to EC50 for Coxsackie virus B3 HA 201 933 by neutral red uptake assay2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID88713Dose required to prevent rhinovirus type 33 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84719inhibitory concentration against mutants of human rhinovirus 14 by standard plague reduction assay by different amino acid substitution1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID557540Antiviral activity against Human rhinovirus 9 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1698665Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus D68 US/KY/14-18953 strain2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID84732Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Ile 42 to Val)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID557776Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A H57Y mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID445047Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by MTS assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
9-Arylpurines as a novel class of enterovirus inhibitors.
AID88707Dose required to prevent rhinovirus type 14 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID86661Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.00 ug/mL1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID134631In vitro hepatic microsomal metabolism in mouse1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID88708Dose required to prevent rhinovirus type 15 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698661Antiviral activity against Coxsackie virus B3 HA 201 933 infected in Vero 76 cells assessed as reduction in virus-induced cytopathic effect by neutral red uptake assay2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID86664Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.08 ug/mL1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID86321Dose required to prevent rhinovirus type 65 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1287140Antiviral activity against Human coxsackievirus B3 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID1698668Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus D68 US/KY/14-18953 by neutral red uptake assay2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID86676Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.35 ug/mL.1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1287134Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Enterovirus 712016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID88712Dose required to prevent rhinovirus type 32 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID644568Antiviral activity against drug-resistant Coxsackievirus B3 Nancy infected in african green monkey Vero cells assessed as inhibition of virus-induced cell death after 3 days by spectrophotometry based MTS/PMS assay2012European journal of medicinal chemistry, Mar, Volume: 49Efficient synthesis and anti-enteroviral activity of 9-arylpurines.
AID557762Antiviral activity against Human rhinovirus 29 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID86674Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.08 ug/mL.1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84729Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Glu 51 to Val)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86667Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.75 ug/mL1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557537Antiviral activity against Human rhinovirus 39 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557538Antiviral activity against Human rhinovirus 15 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID42136Antiviral activity against Poliovirus (PV-1) using plaque reduction assay using BSC1 cells1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID87785Chemotherapeutic index in Hela cells (chemotherapeutic index=50% cytotoxic dose/50% effective dose)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID88375Antiviral activity against Rhinovirus (RV-2) in HeLa cells using CPE/XTT assay1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID557535Antiviral activity against Human rhinovirus 42 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1703114Antiviral activity against Enterovirus A71 infected in human RD cells using HEX-labelled RNA as substrate assessed as inhibition of dsRNA unwinding by measuring accumulation of dsRNA at 0.56 uM treated 8 hpi by gel based flourescence assay2020European journal of medicinal chemistry, Sep-15, Volume: 202Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study.
AID87792Antiviral activity against rhinovirus type 10 in Hela cells1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID557541Antiviral activity against Human poliovirus 3 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1698669Antiviral activity against Poliovirus 1 Mahoney infected in monkey Vero 76 cells assessed as reduction in virus yield by visual inspection method2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1698670Selectivity index, ratio of CC50 for monkey Vero 76 cells to EC50 for Poliovirus 1 Mahoney2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1876071Antiviral activity against HCV2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID557758Antiviral activity against Human enterovirus 71 (strain BRCR) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID86323Dose required to prevent rhinovirus type 70 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84891Anti-HRV activity against HRV-1A strain; Not tested2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
AID1287132Antiviral activity against Human enterovirus 71 infected in monkey African green Vero cells by MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557757Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID88373Antiviral activity against Rhinovirus (RV-14) in HeLa cells using CPE/XTT assay1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID84743% survivors was determined against mutants of human rhinovirus 14 by extended cycle replication assay in 1 ug/mL enviroxime by different amino acid substitution by different amino acid substitution1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID84735Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime. wild type1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID84742% survivors was determined against mutants of human rhinovirus 14 by extended cycle replication assay in 1 ug/mL enviroxime by different amino acid substitution1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86318Dose required to prevent rhinovirus type 48 plaque formation in HeLa cells by 50%ug/mL of agar overlay1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID86666Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.35 ug/mL1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698671Antiviral activity against Poliovirus 1 Mahoney infected in monkey Vero 76 cells assessed as reduction in virus-induced cytopathic effect by neutral red uptake assay2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1876042Antiviral activity against HCV GT1b-genotype assessed as inhibition of viral replication2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID84730Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Gly 72 to Ser)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID1287142Antiviral activity against Human coxsackievirus B5 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557536Antiviral activity against Human rhinovirus 41 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557774Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A V45A mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1698672Selectivity index, ratio of CC50 for monkey Vero 76 cells to EC50 for Poliovirus 1 Mahoney by neutral red uptake assay2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID445048Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
9-Arylpurines as a novel class of enterovirus inhibitors.
AID557759Antiviral activity against Human coxsackievirus A16 (strain G-10) A16 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID86662Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.02 ug/mL1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557533Antiviral activity against Human rhinovirus 63 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557754Antiviral activity against Human poliovirus 2 Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1698666Antiviral activity against Enterovirus D68 US/KY/14-18953 strain infected in RD cells assessed as reduction in virus-induced cytopathic effect by neutral red uptake assay2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID93754Inhibitory concentration required against Human rhinovirus-14 (HRV-14) using plaque reduction assay1999Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10
Short synthesis and anti-rhinoviral activity of imidazo[1,2-a]pyridines: the effect of acyl groups at 3-position.
AID1287139Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus 712016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557756Antiviral activity against Human coxsackievirus A21 (strain Coe) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID126648In vitro hepatic microsomal metabolism in monkey1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID84908Anti-HRV activity against HRV-2 strain2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
AID1287136Antiviral activity against Human coxsackievirus B2 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID86675Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.17 ug/mL.1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698667Cytotoxicity against human RD cells by neutral red uptake assay2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (34.43)18.7374
1990's13 (21.31)18.2507
2000's8 (13.11)29.6817
2010's15 (24.59)24.3611
2020's4 (6.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (9.84%)5.53%
Reviews6 (9.84%)6.00%
Case Studies1 (1.64%)4.05%
Observational0 (0.00%)0.25%
Other48 (78.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pleconaril
WIN 63843: structure given in first source		2.7830
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		4.4511adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
bisindolylmaleimide iv
[no description available]		2.4110indoles;
maleimides
dibucaine
Dibucaine: A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006). cinchocaine : A monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions.		2.2510aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic
fluoxetine
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.		2.2510(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
guanidine
Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.		2.6930carboxamidine;
guanidines;
one-carbon compound
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		2.4110(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		2.4110chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
norfluoxetine
norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation		2.2510(trifluoromethyl)benzenes
olomoucine
olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.		2.41102,6-diaminopurines;
ethanolamines		EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		4.4511alkylamine
tyrphostin a9
[no description available]		2.4110alkylbenzenegeroprotector
2-hydroxybenzylbenzimidazole
2-hydroxybenzylbenzimidazole: RN given refers to cpd without isomeric designation		1.9610
uridine
[no description available]		1.9810uridinesdrug metabolite;
fundamental metabolite;
human metabolite
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.110amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
cytidine
[no description available]		2.110cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
chloroform
Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.		2.3720chloromethanes;
one-carbon compound		carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		2.110L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		1.9910cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		3.2660isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		2.58201,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazoles
[no description available]		2.08101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		2.2510diazine;
pyrazines		Daphnia magna metabolite
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		4.4511beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
2-benzimidazolylguanidine
2-benzimidazolylguanidine: effects chloride efflux in tissue; RN given refers to parent cpd		1.9610aminoimidazole
ribavirin
Rebetron: Rebetron is tradename		5.61511-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
arildone
[no description available]		3.7830methoxybenzenes
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		2.2510delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
3-deazaguanine
3-deazaguanine: structure		2.1310
disoxaril
disoxaril: antipicornavirus agent		3.2660aromatic ether
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		2.0810cephalosporinfungal metabolite
pirodavir
pirodavir: antipicornavirus agent; structure given in first source		340
rmi 15731
RMI 15731: structure		2.3720
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.4110methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
gefitinib
[no description available]		2.4110aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
4',6-dichloroflavan
4',6-dichloroflavan: antirhinovirus cpd; structure given in first source		9.1650
lestaurtinib
[no description available]		2.4110indolocarbazole
canertinib
[no description available]		2.4110monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		2.41102,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
sb 203580
[no description available]		2.4110imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
erlotinib
[no description available]		2.4110aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
ethyl-2-methylthio-4-methyl-5-pyrimidine carboxylate
[no description available]		2.4120
sorafenib
[no description available]		2.4110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.2510macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
pd 166326
PD 166326: a pyrido(2,3-d)pyrimidine src tyrosine kinase inhibitor		2.4110
purvalanol a
6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;		2.4110purvalanol
favipiravir
favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.		2.2510hydroxypyrazine;
organofluorine compound;
primary carboxamide		anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
2'-c-methylcytidine
2'-C-methylcytidine: structure in first source		2.110
chalcone
trans-chalcone : The trans-isomer of chalcone.		3.9840chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
s 1033
[no description available]		2.4110(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
phenylthiourea
Phenylthiourea: Phenylthiourea is a THIOUREA derivative containing a phenyl ring. Depending on their genetic makeup, humans can find it either bitter-tasting or tasteless.. N-phenylthiourea : A member of the class of thioureas that is thiourea in which one of the hydrogens is replaced by a phenyl group. Depending on their genetic makeup, humans find it either very bitter-tasting or tasteless. This unusual property resulted in N-phenylthiourea being used in paternity testing prior to the advent of DNA testing.		2.4120thioureasEC 1.14.18.1 (tyrosinase) inhibitor
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol
[no description available]		2.4110substituted aniline
n-phenyl-n'-3-hydroxyphenylthiourea
[no description available]		2.4120
rhodanine
2-mercaptothiazolinone: metabolite in urine from persons exposed to CS2; structure		3.0610thiazolidinone
u 0126
U 0126: protein kinase kinase inhibitor; structure in first source		2.4110aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		2.41101,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
alsterpaullone
alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.		2.4110C-nitro compound;
caprolactams;
organic heterotetracyclic compound		anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
quercetin
[no description available]		2.37207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
genistein
[no description available]		2.41107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
pachypodol
pachypodol: new flavonoid isolated from Pachypodanthium confine; from Chinese herb Agastache folium; structure. pachypodol : A trimethoxyflavone that is quercetin in which the hydroxy groups at position 3, 7 and 3' are replaced by methoxy groups. It has been isolated from Combretum quadrangulare and Euodia elleryana.		2.3720dihydroxyflavone;
trimethoxyflavone		antiemetic;
plant metabolite
rottlerin
rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.		2.4110aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
brefeldin a
[no description available]		1.9910macrolide antibioticPenicillium metabolite
alvocidib
alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.		2.4110dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide
[no description available]		2.4110pyrimidines
bosutinib
4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source		2.4110aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
su 11248
[no description available]		2.4110monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
palbociclib
[no description available]		2.4110aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
thallium
Thallium: A heavy, bluish white metal, atomic number 81, atomic weight [204.382; 204.385], symbol Tl.. thallium : A metallic element first identified and named from the brilliant green line in its flame spectrum (from Greek thetaalphalambdalambdaomicronsigma, a green shoot).		2.0510boron group element atom
gw-5074
[no description available]		2.4720
enviradene
[no description available]		2.8940
ro 09-0410
Ro 09-0410: structure given in first source		8.9840
rupintrivir
rupintrivir: a rhinovirus 3C protease inhibitor		2.110
everolimus
[no description available]		2.4110cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
pd 184352
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source		2.4110aminobenzoic acid
bibx 1382bs
BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001		2.4110substituted aniline
vacuolin-1
vacuolin-1: inhibits Ca2-dependent lysosomal exocytosis		2.4110
pd 0325901
mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).		2.4110difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound		antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin
midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.		2.4110benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
tofacitinib
tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.		2.4110N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
osu 03012
OSU 03012: a PDK-1 inhibitor; structure in first source		2.4110antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
bx795
BX795: structure in first source		2.4110ureas
azd 6244
AZD 6244: a MEK inhibitor		2.4110benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
a 443654
A 443654: an Akt kinase inhibitor; structure in first source		2.4110indoles
apilimod
[no description available]		2.4110
pik 75
PIK 75: structure in first source		2.4110
saracatinib
[no description available]		2.4110aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		2.5820
regorafenib
[no description available]		2.4110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
bi 2536
[no description available]		2.4110
crizotinib
Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)		2.41103-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
trametinib
[no description available]		2.4110acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
pha 767491
PHA 767491: a Cdc7 inhibitor; structure in first source		2.4110pyrrolopyridine
dactolisib
dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.		2.4110imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
[no description available]		2.4110organochlorine compound
hbbpc
[no description available]		2.4120
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		1.97101,2-diacyl-sn-glycero-3-phosphocholine
azd8330
[no description available]		2.4110pyridinecarboxamide
fedratinib
fedratinib: a selective small-molecule inhibitor of JAK2		2.4110sulfonamide
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source		2.4110
phosphatidylinositol 4-phosphate
phosphatidylinositol 4-phosphate : A phosphatidylinositol monophosphate carrying the phosphate group at the 4-position.		2.0710
pci 32765
ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.		2.4110acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
mk 2206
MK 2206: a protein kinase inhibitor and antineoplastic agent		2.4110organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.		2.4110aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound		anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
incb-018424
[no description available]		2.4110nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fit-039
FIT-039: CDK9 inhibitor; structure in first source		2.4110
azd2014
vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source		2.4110
bay 869766
[no description available]		2.4110
baricitinib
[no description available]		2.4110azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
piperidines
Piperidines: A family of hexahydropyridines.		2.5220
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide: a protein kinase inhibitor; structure in first source		2.4110
ly2784544
[no description available]		2.4110pyridazines
sb 1518
[no description available]		2.4110
dinaciclib
[no description available]		2.4110pyrazolopyrimidine
gilteritinib
gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.		2.4110aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
glpg0634
[no description available]		2.4110
delgocitinib
delgocitinib: a Janus kinase inhibitor. delgocitinib : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan.		2.4110azaspiro compound;
N-acylazetidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound;
tertiary carboxamide		anti-inflammatory drug;
antipsoriatic;
antiseborrheic;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
incb039110
INCB039110: a JAK1 inhibitor; structure in first source		2.4110
vx-970
berzosertib: an ATR kinase inhibitor		2.4110sulfonamide
ldc4297
LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.		2.4110aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound		antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
at 9283
[no description available]		2.4110
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		4.45112-aminopurines;
oxopurine		antimetabolite;
antiviral drug
guanine
[no description available]		2.13102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ag-879
AG-879: structure given in first source		2.4110
hesperadin
[no description available]		2.4110
ConditionIndicatedRelationship StrengthStudiesTrials
Enterovirus Infections
Diseases caused by ENTEROVIRUS.		04.9960
2019 Novel Coronavirus Disease
[description not available]		02.4110
Viral Diseases
[description not available]		04.7221
Virus Diseases
A general term for diseases caused by viruses.		04.7221
Autoimmune Diabetes
[description not available]		02.2510
Coxsackie Virus Infections
[description not available]		02.730
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.2510
Catarrh
Inflammation of a mucous membrane with increased flow of mucous in humans or animals. Catarrh is used mostly in a historical context.		09.16115
Common Cold
A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.		09.16115
Foot and Mouth Disease
[description not available]		02.110
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		02.1310
Encephalitis, Polio
[description not available]		03.3220
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		03.3220
Cerebrospinal Fluid Rhinorrhea
Discharge of cerebrospinal fluid through the nose. Common etiologies include trauma, neoplasms, and prior surgery, although the condition may occur spontaneously. (Otolaryngol Head Neck Surg 1997 Apr;116(4):442-9)		03.3411
Conjunctivitis, Acute Hemorrhagic
A highly contagious disease characterized by subconjunctival hemorrhage, sudden swelling of the eyelids and congestion, redness, and pain in the eye. Epidemic conjunctivitis caused by Enterovirus 70 (EV-70) was first described in Africa in 1969. It is caused also by Coxsackievirus A24 variant (CA24v). Epidemics by this organism have appeared most frequently in Asia.		01.9810
Infections, Picornaviridae
[description not available]		03.7720
Grippe
[description not available]		04.2711
Infections, Respiratory
[description not available]		04.2711
Influenza, Human
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.		04.2711
Pneumonia, Viral
Inflammation of the lung parenchyma that is caused by a viral infection.		04.2711
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		04.2711
Echo Virus Infections
[description not available]		02.8810
chemdatabank.com